P/25/2011 - paediatric investigation plan

Briakinumab

Key facts

• Active Substance:
  Briakinumab
• Therapeutic area:
  Dermatology
• Decision number:
  P/25/2011
• PIP number:
  P/25/2011
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Psoriasis vulgaris
• Route(s) of administration:
  Subcutaneous use
• Contact for public enquiries:

  AbbVie Ltd

  United Kingdom; E-mail: [e-mail]; Tel. [phone]; Fax [phone]

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  26/01/2011

Decision

P/25/2011: EMA decision of 26 January 2011 on the acceptance of a modification of an agreed paediatric investigation plan for briakinumab (EMEA-000552-PIP01-09-M01) in accordance with Regulation (EC) No 1901/2006 of the...

AdoptedReference Number: EMA/30702/2011